Abstract
Background: This study attempted to combine Serum Metabolic Biomarkers with clinical factors to construct nomograms to predict outcomes of patients with advanced non-small cell lung cancer( NSCLC) receiving first-line chemoimmunotherapy (CIT). Methods: A retrospective analysis was conducted on 112 patients with stage IIIC–IVB NSCLC receiving first-line CIT between January 2019 and January 2022.The Serum Metabolic Biomarker including lactate dehydrogenase (LDH), lactate (LAC), uric acid (UA), albumin (ALB), triglycerides (TG) and total cholesterol (TC) were examined at baseline. Patients were stratified into responders (R)and non-responders(NR) based on treatment efficacy. Progression-free survival (PFS) and overall survival (OS) were assessed via Kaplan-Meier analysis. Nomograms was created based on the multivariate Cox regression analysis to predict OS and PFS. The nomogram was internally validated using bootstrap resampling. Nomogram was assessed using the concordance index (C-index), the time-dependent area under the receiver operating curves(ROC), calibration curves, and decision curve analysis (DCA). Results: Non-diabetic status, PD-L1 expression≥50%, low LDH, LAC, UA, TC and high ALB correlated with better response (all PConclusion: Serum metabolic biomarkers (LDH, LAC, UA, ALB, TG) hold significant value in predicting outcomes of chemoimmunotherapy in advanced NSCLC. The nomograms provide accurate and practical tools to guide personalized treatment decisions.

This publication has 34 references indexed in Scilit: